Gritstone bio GRTS Stock
Gritstone bio Price Chart
Gritstone bio GRTS Financial and Trading Overview
| Gritstone bio stock price | 0.03 USD |
| Previous Close | 2.26 USD |
| Open | 2.26 USD |
| Bid | 0 USD x 3100 |
| Ask | 0 USD x 1800 |
| Day's Range | 2.25 - 2.37 USD |
| 52 Week Range | 1.64 - 5.85 USD |
| Volume | 550.91K USD |
| Avg. Volume | 617.32K USD |
| Market Cap | 200.94M USD |
| Beta (5Y Monthly) | 0.53841 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.6 USD |
GRTS Valuation Measures
| Enterprise Value | 103.92M USD |
| Trailing P/E | N/A |
| Forward P/E | -1.7121211 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 13.222658 |
| Price/Book (mrq) | 1.4089776 |
| Enterprise Value/Revenue | 6.838 |
| Enterprise Value/EBITDA | -0.87 |
Trading Information
Gritstone bio Stock Price History
| Beta (5Y Monthly) | 0.53841 |
| 52-Week Change | 1.80% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 5.85 USD |
| 52 Week Low | 1.64 USD |
| 50-Day Moving Average | 2.36 USD |
| 200-Day Moving Average | 2.78 USD |
GRTS Share Statistics
| Avg. Volume (3 month) | 617.32K USD |
| Avg. Daily Volume (10-Days) | 712.39K USD |
| Shares Outstanding | 88.91M |
| Float | 66.83M |
| Short Ratio | 5.96 |
| % Held by Insiders | 2.42% |
| % Held by Institutions | 53.37% |
| Shares Short | 4.4M |
| Short % of Float | 5.65% |
| Short % of Shares Outstanding | 4.95% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -830.95% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -34.81% |
| Return on Equity (ttm) | -75.59% |
Income Statement
| Revenue (ttm) | 15.2M USD |
| Revenue Per Share (ttm) | 0.16 USD |
| Quarterly Revenue Growth (yoy) | -66.00000000000000000000000000000000% |
| Gross Profit (ttm) | -91458000 USD |
| EBITDA | -119511000 USD |
| Net Income Avi to Common (ttm) | -124753000 USD |
| Diluted EPS (ttm) | -1.24 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 145.81M USD |
| Total Cash Per Share (mrq) | 1.64 USD |
| Total Debt (mrq) | 48.78M USD |
| Total Debt/Equity (mrq) | 34.63 USD |
| Current Ratio (mrq) | 6.273 |
| Book Value Per Share (mrq) | 1.604 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -122585000 USD |
| Levered Free Cash Flow (ttm) | -61789000 USD |
Profile of Gritstone bio
| Country | United States |
| State | CA |
| City | EmeryVille |
| Address | 5959 Horton Street |
| ZIP | 94608 |
| Phone | 510 871 6100 |
| Website | https://gritstonebio.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 233 |
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, a neoantigen-based immunotherapy, which is in Phase 2/3 clinical trials for the treatment of solid tumors, including microsatellite stable colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors. In addition, it develops CORAL, a SARS-CoV-2 vaccine platform designed to deliver spike and additional SARS-CoV-2 T cell epitopes for protection and broader immunity against SARS-CoV-2 variants; and a therapeutic vaccine candidate designed to treat and cure human immunodeficiency virus (HIV) infection. Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Q&A For Gritstone bio Stock
What is a current GRTS stock price?
Gritstone bio GRTS stock price today per share is 0.03 USD.
How to purchase Gritstone bio stock?
You can buy GRTS shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Gritstone bio?
The stock symbol or ticker of Gritstone bio is GRTS.
Which industry does the Gritstone bio company belong to?
The Gritstone bio industry is Biotechnology.
How many shares does Gritstone bio have in circulation?
The max supply of Gritstone bio shares is 146.27M.
What is Gritstone bio Price to Earnings Ratio (PE Ratio)?
Gritstone bio PE Ratio is 0.00000000 now.
What was Gritstone bio earnings per share over the trailing 12 months (TTM)?
Gritstone bio EPS is 0 USD over the trailing 12 months.
Which sector does the Gritstone bio company belong to?
The Gritstone bio sector is Healthcare.
Gritstone bio GRTS included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 17277.34 USD — |
-0.61
|
7.72B USD — | 17128.71 USD — | 17467.35 USD — | — - | 7.72B USD — |
| NASDAQ Global Select Market Com NQGS | 8452.28 USD — |
-0.61
|
— — | 8378.66 USD — | 8543.96 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4158.56 USD — |
+0.66
|
— — | 4144.83 USD — | 4202.15 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 925.29 USD — |
+0.19
|
— — | 921.75 USD — | 934.48 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4157.43 USD — |
+0.21
|
— — | 3927.42 USD — | 4157.43 USD — | — - | — — |
- {{ link.label }} {{link}}